LYEL
Lyell Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.80
+8.37%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$8.00
From 52W high−77.20%
Volume212805.00
Market cap$215.65M
P/E (TTM)—
P/S (TTM)7986.9x
Div yield—
Key dataOct 19, 2026
Open
$8.00
From 52W high
−77.20%
Volume
212805.00
Market cap
$215.65M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
35.7
MomentumView details →
1D Return
+8.37%
YTD Return
−72.32%
SummaryUpdated Jun 1, 2026
Lyell Immunopharma, Inc. (NASDAQ:LYEL) is a clinical-stage biotechnology company founded in 2018 and headquartered in South San Francisco, California. The company went public in June 2021 and specializes in developing novel T cell therapies for patients with solid tumors. Lyell focuses on overcoming the limitations of current cancer immunotherapies by reprogramming T cells to maintain their effectiveness against cancer over extended periods, addressing a critical challenge in oncology where T cells often become exhausted and lose their cancer-fighting capabilities.
Similar companies
Latest newsMore news →
Lyell Immunopharma completed the technology transfer of its GCC-targeted CAR T-cell candidate LYL273 to its LyFE Manufacturing Center in Bothell, Washington, following FDA review.39d agoLyell Immunopharma reported its Q2 2026 financial results, with revenue of $4,000, a GAAP net loss of $44.8 million, and cash and marketable securities of $228.0 million as of June 30, 2026.75d ago